All Valneva SE articles
-
NewsValneva and LimmaTech team up to accelerate tetravalent Shigella vaccine candidate
Valneva SE and LimmaTech Biologics AG have entered into a strategic partnership and exclusive licensing agreement for the development, manufacturing and commercialization of Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis.
-
NewsValneva vaccinates first participant in pediatric trial of single-shot Chikungunya vaccine
Valneva SE has announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and immunogenicity in children of two different dose levels of Valneva’s single-shot chikungunya vaccine.
